Management of glucocorticoids-induced osteoporosis: Role of teriparatide

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 305-310

  Migliaccio, Silvia ^a   Brama, Marina ^a   Malavolta, Nazzarena ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Glucocorticoids; Osteoblasts; Osteoclasts; Osteoporosis; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; GLUCOCORTICOID; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID;

BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HORMONE ACTION; HUMAN; LUMBAR SPINE; OFF LABEL DRUG USE; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; VERTEBRA FRACTURE;

EID: 76649127898     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s3940     Document Type: Review

References (64)

1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp. 1932;50:137-195.
2. Lukert, B. Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. Academic Press, San Diego, CA, 1996;801-820.
3. Fitzpatrick LA. Glucocorticoid-induced osteoporosis. In: Marcus R (ed) Osteoporosis. Blackwell Scientific Publications, Boston, MA, 1994. p. 202-226.
4. NIH Consensus Development Panel on Osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-95.
5. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord. 2001;2:65-73.
6. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and treatment. Ann Intern Med. 1990;112:344-346.
7. LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990;8:39-51.
8. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004;15:323-328.
9. Dempster D. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res. 1989;4:137-141.
10. Dalle Carbonare L, Giannini S. Bone microarchitecture as an important determinant of bone strength. J Endocrinol Invest. 2004;27:99-105.
11. Migliaccio S, Falcone S, Spera G. Bone modeling and remodeling: from biology to clinical application. Ageing Clin Exp Res. 2007;19S:5-10.
12. Weinstein RS, Jilka RL, Parfi tt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282.
13. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145:1835-1841.
14. Heitzer MD, Wolf IM, Sanchez ER, Witchel SF, DeFranco DB. Glucocorticoid receptor physiology. Rev Endocr Metab Disord. 2007;8:321-330.
15. Bhargava A, Pearce D. Mechanisms of mineralcorticoid action: determinants of receptor specifi city and actions of regulated gene products. Trends Endocrinol Metab. 2004;15:147-153.
16. Migliaccio S, Marino M. Estrogens and estrogen receptors: new actors in the plot of transcriptional regulation of genomic responses. Calcif Tissue Int. 2003;72:181-182.
17. Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet. 2000;356:87-89.
18. Plotkin LI, Manolagas SC, Bellido T. Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis. J Biol Chem. 2007;282:24120-24130.
19. Beavan S, Horner A, Bord S, Ireland D, Compston J. Colocalization of glucocorticoid and mineralcorticoid receptors in human bone. J Bone Miner Res. 2001;16:1496-1504.
20. Huang L, Xu J, Kumta SM, Zheng MH. Gene expression of glucocorticoid receptor α and β in giant cell tumor of bone: evidence of glucocorticoid-stimulated osteoclastogenesis by stromal-like tumor cells. Mol Cell Endocrinol. 2001;181:199-206.
21. Wong MM, Rao LG, Ly H, Hamilton L, Tong J, Sturtridge W. Long-term effects of physiologic concentrations of dexamethasone on human bone-derived cells. J Bone Miner Res. 1990;5:803-813.
22. 3 on osteogenic differentiation of human bone marrow stromal cells in vitro. Arch Oral Biol. 1994;39:941-947.
23. Cheng SL, Yang JW, Rifas L, Zhang SF, Avioli LV. Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of osteoblastic phenotype by dexamethasone. Endocrinology. 1994;134:277-286.
24. Cooper MS, Hewison M, Steward PM (1999) Glucocorticoid activity, inactivity and the osteoblast. J Endocrinol 163:159-164.
25. Delany AM, Gabbitas BY, Canalis E. Cortisol downregulates osteoblast α-1(I) procollagen mRNA by transcriptional and posttranscriptional mechanisms. J Cell Biochem. 1995;57:488-494.
26. Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab. 2004;89:3332-3336.
27. Leclerc N, Luppen CA, Ho VV, et al. Gene expression profi ling of glucocorticoid-inhibited osteoblasts. J Mol Endocrinol. 2004; 33:175-193.
28. Olkku A, Bodine PV, Linnala-Kankkunen A, Mahonen A. Glucocorticoids induce glutamine synthetase expression in human osteoblastic cells: a novel observation in bone. Bone. 2004;34:320-329.
29. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagia R. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Comm. 2004;318:259-264.
30. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
31. Boling EP. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis. Clin Ther. 2004;1:1-14.
32. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab. 2006;17:144-149.
33. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67:277-285.
34. Cosman F. Parathyroid hormone treatment for osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2008;15:495-501.
35. Kaufman JM, Goemaere S. Osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2008;22:787-812.
36. Blick SD, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs. 2008;68:2709-2737.
37. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40:1434-1446.
38. Doggett TA, Swarthout JT, Jefcoat SC Jr, et al. Parathyroid hormone inhibits c-jun N-terminal kinase activity in rat osteoblastic cells by a protein kinase A-dependent pathway. Endocrinology. 2002;143:1880-1888.
39. Sabatini M, Lesur C, Pacherie M, et al. Effects of parathyroid hormone and agonists of the adenylyl cyclase and protein kinase C pathways on bone cell proliferation. Bone. 1996;18:59-65.
40. Gesty-Palmer D, Chen M, Reiter E, et al. Distinct beta-arrestin and G-protein-dependent pathways for parathyroid hormone receptorstimulated ERK 1/2 activation. J Biol Chem. 2006;281:10856-10864.
41. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995;136:3632-3638.
42. Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone. 2008.
43. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfi tt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104:439-446.
44. Wang BL, Dai CL, Quan JX, et al. Parathyroid hormone regulates osterix and Runx2 mRNA expression predominantly through protein kinase A signaling in osteoblast-like cells. J Endocrinol Investig. 2006;29:101-108.
45. Datta NS, Pettway GJ, Chen C, Koh AJ, McCauley LK. Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone mineral Res. 2007;22:951-964.
46. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357:905-916.
47. Garrett IR. Anabolic agents and the bone morphogenetic protein pathway. Curr Dev Top Biol. 2007;78:127-171.
48. Kakar S, Einhorn TA, Vora S, et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Mineral Res. 2007;22:1903-1912.
49. Kaback LA, Soung do Y, Naik A, et al. Teriparatide (1-34 human PTH) regulation of osterix during fracture repair. J Cell Biochem. 2008;105:219-226.
50. Bodine PV, Seestaller-Wehr L, Kharode YP, Bex FJ, Komm BS. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol. 2007;210:352-357.
51. Blalock SJ, Norton LL, Patel RA, Dooley MA. Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 2005;53:732-739.
52. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93:105-111.
53. Compston J. UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences. Curr Rheumatol Rep. 2004;6:66-69.
54. Abadie EC, Devogealer JP, Ringe JD, et al. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. Semin Arthritis Rheum. 2005;35:1-4.
55. Pereira RG, Delany AM, Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone. 2002;30:685-691.
56. Rosen CJ. What's new with PTH in osteoporosis: where are we and where are we headed? Trends Endocrinol Metab. 2004;15:229-33.
57. Seeman E. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis. Osteoporos Int. 2003;14:S2-S8.
58. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis Int. 2000;11:434-442.
59. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteop Int. 2003;14:77-81.
60. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028-2039.
61. Losada BR, Zanchetta JR, Zerbini C, et al. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from Hispanic and non-hispanic cohorts. J Clin Densitom. 2008.
62. Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab. 2004;89:3332-336.
63. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res. 2000;15:944-951.
64. Saag K, Zanchetta J, Devogelaer J, Adler R, SeeK, Dalsky G. Teriparatide or alendronate in glucocorticoid-induced osteoporosis: data from 36 months trial. Annual Congress of the Am Soc Bone Mineral Res Abs. 2008;1171.